TerminatedPhase 1

A Study of Participants With Chronic Kidney Disease Previously Treated With REACT

Stopped: business decision

United States1 participantsStarted 2023-07-11

Plain-language summary

The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.

Who can participate

Age range30 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. The participant has received REACT in a previous trial for treatment of chronic kidney disease and completed their parent protocol follow up period.
✓. The participant is male or female, 30 to 80 years of age on the date of informed consent.
✓. The participant has a documented clinical diagnosis of an eGFR greater than or equal to 14 and less than or equal to 50 mL/min/1.73m2, not requiring renal dialysis.
✓. The participant has stable blood pressure and is maintained on a stable antihypertensive medication regimen if treatment for hypertension is necessary.

Exclusion criteria

✕. The participant has a history of renal transplantation.
✕. The participant has received dialysis for more than 30 days.
✕. The participant has received any other investigational products after completion of REACT injections within 3 months of screening.
✕. The participant has a urinary albumin-to-creatinine ratio (UACR) of greater than 5,000 mg/g.
✕. The participant has hemoglobin levels less than 10 g/dL and is not responsive to the standard medical intervention for CKD-related anemia prior to screening.

What they're measuring

Primary Endpoints is as follows:

Timeframe: through 12 months after last supplemental injection

Trial details

NCT IDNCT05694169

SponsorProkidney

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-03-19

View on ClinicalTrials.gov More Diabetic Kidney Disease trials